Is PDSB or MIST more profitable?

Milestone Pharmaceuticals' return on equity of -339.33% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% Milestone Pharmaceuticals N/A -339.33% -61.79%

Is PDSB or NRXP more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% NRx Pharmaceuticals N/A N/A -202.92%

Is HUMA or PDSB more profitable?

PDS Biotechnology has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. PDS Biotechnology's return on equity of -346.02% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% PDS Biotechnology N/A -346.02% -102.36%

PDS Biotechnology (PDSB) Competitors

$0.76 +0.04 (+5.95%)

Closing price 04:00 PM Eastern

Extended Trading

$0.76 +0.01 (+0.66%)

As of 05:31 PM Eastern

Compare

PDSB vs. MIST, NRXP, ADCT, LENZ, and HUMA

Should you buy PDS Biotechnology stock or one of its competitors? MarketBeat compares PDS Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PDS Biotechnology include Milestone Pharmaceuticals (MIST), NRx Pharmaceuticals (NRXP), ADC Therapeutics (ADCT), LENZ Therapeutics (LENZ), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry.

How does PDS Biotechnology compare to Milestone Pharmaceuticals?

PDS Biotechnology (NASDAQ:PDSB) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

PDS Biotechnology has higher earnings, but lower revenue than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Milestone Pharmaceuticals' return on equity of -339.33% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

In the previous week, Milestone Pharmaceuticals had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Milestone Pharmaceuticals and 0 mentions for PDS Biotechnology. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat PDS Biotechnology's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
PDS Biotechnology	Neutral
Milestone Pharmaceuticals	Very Positive

PDS Biotechnology presently has a consensus target price of $9.00, suggesting a potential upside of 1,084.21%. Milestone Pharmaceuticals has a consensus target price of $7.25, suggesting a potential upside of 489.43%. Given PDS Biotechnology's higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

PDS Biotechnology has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Summary

Milestone Pharmaceuticals beats PDS Biotechnology on 9 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to NRx Pharmaceuticals?

PDS Biotechnology (NASDAQ:PDSB) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PDS Biotechnology currently has a consensus price target of $9.00, suggesting a potential upside of 1,084.21%. NRx Pharmaceuticals has a consensus price target of $38.25, suggesting a potential upside of 757.62%. Given PDS Biotechnology's higher probable upside, equities analysts plainly believe PDS Biotechnology is more favorable than NRx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

NRx Pharmaceuticals' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
NRx Pharmaceuticals	N/A	N/A	-202.92%

In the previous week, NRx Pharmaceuticals had 4 more articles in the media than PDS Biotechnology. MarketBeat recorded 4 mentions for NRx Pharmaceuticals and 0 mentions for PDS Biotechnology. NRx Pharmaceuticals' average media sentiment score of 0.94 beat PDS Biotechnology's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
PDS Biotechnology	Neutral
NRx Pharmaceuticals	Positive

NRx Pharmaceuticals has higher revenue and earnings than PDS Biotechnology. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
NRx Pharmaceuticals	$1.23M	131.37	-$28.62M	-$1.09	N/A

PDS Biotechnology has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market.

Summary

NRx Pharmaceuticals beats PDS Biotechnology on 8 of the 14 factors compared between the two stocks.

How does PDS Biotechnology compare to ADC Therapeutics?

PDS Biotechnology (NASDAQ:PDSB) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

PDS Biotechnology has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
ADC Therapeutics	$81.36M	1.99	-$142.62M	-$1.05	N/A

In the previous week, ADC Therapeutics had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 1 mentions for ADC Therapeutics and 0 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.00 equaled ADC Therapeutics'average media sentiment score.

Company	Overall Sentiment
PDS Biotechnology	Neutral
ADC Therapeutics	Neutral

PDS Biotechnology has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
ADC Therapeutics	-173.02%	N/A	-44.70%

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PDS Biotechnology has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market.

PDS Biotechnology currently has a consensus target price of $9.00, suggesting a potential upside of 1,084.21%. ADC Therapeutics has a consensus target price of $6.25, suggesting a potential upside of 390.20%. Given PDS Biotechnology's higher possible upside, equities research analysts plainly believe PDS Biotechnology is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

ADC Therapeutics beats PDS Biotechnology on 7 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to LENZ Therapeutics?

PDS Biotechnology (NASDAQ:PDSB) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

PDS Biotechnology has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PDS Biotechnology has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
LENZ Therapeutics	$19.09M	8.47	-$82.13M	-$3.60	N/A

In the previous week, LENZ Therapeutics had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for LENZ Therapeutics and 0 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.00 beat LENZ Therapeutics' score of -0.32 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Neutral
LENZ Therapeutics	Neutral

PDS Biotechnology currently has a consensus target price of $9.00, indicating a potential upside of 1,084.21%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 477.52%. Given PDS Biotechnology's higher probable upside, research analysts clearly believe PDS Biotechnology is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

PDS Biotechnology has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

Summary

PDS Biotechnology beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to Humacyte?

Humacyte (NASDAQ:HUMA) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

PDS Biotechnology has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. PDS Biotechnology's return on equity of -346.02% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
PDS Biotechnology	N/A	-346.02%	-102.36%

PDS Biotechnology has lower revenue, but higher earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	73.01	-$40.83M	-$0.57	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Humacyte has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

44.7% of Humacyte shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Humacyte currently has a consensus target price of $6.25, indicating a potential upside of 831.72%. PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 1,084.21%. Given PDS Biotechnology's higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Humacyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Humacyte had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Humacyte and 0 mentions for PDS Biotechnology. Humacyte's average media sentiment score of 0.20 beat PDS Biotechnology's score of 0.00 indicating that Humacyte is being referred to more favorably in the media.

Company	Overall Sentiment
Humacyte	Neutral
PDS Biotechnology	Neutral

Summary

Humacyte beats PDS Biotechnology on 9 of the 15 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDSB vs. The Competition

Export

Metric	PDS Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.50M	$3.65B	$6.81B	$12.41B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.13	20.79	27.00	24.19
Price / Sales	N/A	321.78	518.84	94.59
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	4.22	8.17	10.67	6.26
Net Income	-$34.50M	$23.81M	$3.60B	$331.76M
7 Day Performance	1.06%	-1.16%	-0.37%	-1.10%
1 Month Performance	-20.42%	2.60%	1.85%	-1.27%
1 Year Performance	-33.91%	45.44%	25.51%	18.85%

PDS Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDSB PDS Biotechnology	2.4528 of 5 stars	$0.76 +6.0%	$9.00 +1,084.2%	-37.6%	$42.50M	N/A	N/A	20
MIST Milestone Pharmaceuticals	2.5132 of 5 stars	$1.29 +0.4%	$7.25 +464.2%	-25.3%	$160.48M	$1.55M	N/A	30
NRXP NRx Pharmaceuticals	3.3922 of 5 stars	$4.35 +4.7%	$38.25 +780.1%	+42.2%	$158.54M	$1.23M	N/A	2	News Coverage Positive News
ADCT ADC Therapeutics	2.9534 of 5 stars	$1.25 -0.2%	$6.25 +400.8%	-58.5%	$158.35M	$81.36M	N/A	310	Gap Down
LENZ LENZ Therapeutics	2.4837 of 5 stars	$5.07 -3.1%	$29.80 +487.8%	-85.3%	$158.26M	$19.09M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDSB) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDS Biotechnology (PDSB) Competitors

PDSB vs. MIST, NRXP, ADCT, LENZ, and HUMA

How does PDS Biotechnology compare to Milestone Pharmaceuticals?

Summary

How does PDS Biotechnology compare to NRx Pharmaceuticals?

Summary

How does PDS Biotechnology compare to ADC Therapeutics?

Summary

How does PDS Biotechnology compare to LENZ Therapeutics?

Summary

How does PDS Biotechnology compare to Humacyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PDS Biotechnology (PDSB) Competitors

PDSB vs. MIST, NRXP, ADCT, LENZ, and HUMA

How does PDS Biotechnology compare to Milestone Pharmaceuticals?

Which has stronger earnings & valuation, PDSB or MIST?

Do institutionals and insiders have more ownership in PDSB or MIST?

Is PDSB or MIST more profitable?

Does the media refer more to PDSB or MIST?

Do analysts recommend PDSB or MIST?

Which has more volatility and risk, PDSB or MIST?

Summary

How does PDS Biotechnology compare to NRx Pharmaceuticals?

Do insiders and institutionals have more ownership in PDSB or NRXP?

Do analysts recommend PDSB or NRXP?

Is PDSB or NRXP more profitable?

Does the media refer more to PDSB or NRXP?

Which has higher valuation & earnings, PDSB or NRXP?

Which has more risk & volatility, PDSB or NRXP?

Summary

How does PDS Biotechnology compare to ADC Therapeutics?

Which has stronger earnings & valuation, PDSB or ADCT?

Does the media prefer PDSB or ADCT?

Is PDSB or ADCT more profitable?

Do insiders & institutionals hold more shares of PDSB or ADCT?

Which has more volatility and risk, PDSB or ADCT?

Do analysts rate PDSB or ADCT?

Summary

How does PDS Biotechnology compare to LENZ Therapeutics?

Which has more risk & volatility, PDSB or LENZ?

Do insiders & institutionals believe in PDSB or LENZ?

Which has stronger valuation and earnings, PDSB or LENZ?

Does the media prefer PDSB or LENZ?

Do analysts rate PDSB or LENZ?

Is PDSB or LENZ more profitable?

Summary

How does PDS Biotechnology compare to Humacyte?

Is HUMA or PDSB more profitable?

Which has higher valuation & earnings, HUMA or PDSB?

Which has more volatility and risk, HUMA or PDSB?

Do insiders & institutionals have more ownership in HUMA or PDSB?

Do analysts rate HUMA or PDSB?

Does the media prefer HUMA or PDSB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools